Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Fusizone** is a topical fixed-dose cream manufactured by Batterjee Pharma containing **fusidic acid 2%** and **betamethasone valerate 0.1%**. Fusidic acid is a topical antibacterial that inhibits bacterial protein synthesis through elongation factor G, while betamethasone valerate is a topical corticosteroid that activates glucocorticoid receptors to reduce inflammation, erythema, swelling, and pruritus. It is indicated for inflammatory dermatoses, including eczema and dermatitis, when complicated by susceptible bacterial infection. ([sdi.sfda.gov.sa](https://sdi.sfda.gov.sa/home/Result?drugId=3942))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Fusizone.